The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | PD-L1 inhibitors in r/r Hodgkin lymphoma
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, describes current treatment options for patients with relapsed/refractory Hodgkin lymphoma who have progressed or are ineligible for transplant. Whilst PD-L1 inhibitors such as pembrolizumab and nivolumab have shown to efficacious in patients, producing durable responses remains a barrier. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
